Advertisement
Screener

RAFAEL HOLDINGS, INC. (RFL) Proceeds from Related Party Debt

2.8 / 5 stars · 68/120 Roast Me

RAFAEL HOLDINGS, INC. Proceeds from Related Party Debt

RAFAEL HOLDINGS, INC. (RFL) reported Proceeds from Related Party Debt of $886.00 thousand for the 12-month period ending 2018-07-31, per its 10-K filed 2019-10-04.

Discontinued › Cash Flow › Financing Activities

us-gaap:ProceedsFromRelatedPartyDebt · last filed 2019-10-04

  • RAFAEL HOLDINGS, INC. proceeds from related party debt for the quarter ending 2017-07-31 was $1.49M.
  • RAFAEL HOLDINGS, INC. proceeds from related party debt for the quarter ending 2017-04-30 was $441.00K.
  • RAFAEL HOLDINGS, INC. proceeds from related party debt for fiscal 2018 was $886.00K, a 92.13% decline from fiscal 2017.
  • RAFAEL HOLDINGS, INC. proceeds from related party debt for fiscal 2017 was $11.26M, a 70.14% increase from fiscal 2016.
  • RAFAEL HOLDINGS, INC. proceeds from related party debt for fiscal 2016 was $6.62M.
Period endProceeds from Related Party Debt 3 monthProceeds from Related Party Debt 6 monthProceeds from Related Party Debt 9 monthProceeds from Related Party Debt 12 month
2018-07-31$886.00K
10-K · filed 2019-10-04
2018-01-31$900.00K
10-Q · filed 2019-03-12
2017-07-31$1.49M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-10-15
$1.93M
derived: sum of 2 quarters · filed 2018-10-15
$11.26M
10-K · filed 2018-10-15
2017-04-30$441.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-06-11
$9.77M
10-Q · filed 2018-06-11
2017-01-31$9.33M
10-Q · filed 2018-03-12
2016-07-31$6.62M
10-K · filed 2018-10-15

Similar stocks

Stock NameCountryMarket CapPE Ratio
Aditxt, Inc. (ADTX)United States$0.000B
CDT Equity Inc. (CDT)United States$0.000B-0.01
Protagenic Therapeutics, Inc.\new (PTIX)United States$0.001B
Decoy Therapeutics Inc. (DCOY)United States$0.002B-0.27
Nexentis Technologies Inc. (NXTS)$0.002B
ORAGENICS INC (OGEN)United States$0.002B
JUPITER NEUROSCIENCES, INC. (JUNS)United States$0.002B-0.02
BioXcel Therapeutics, Inc. (BTAI)United States$0.002B
ZyVersa Therapeutics, Inc. (ZVSA)United States$0.002B
Matinas BioPharma Holdings, Inc. (MTNB)United States$0.003B